BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mineralys Therapeutics reported a significant miss in its earnings per share (EPS) for the fourth quarter of 2024, recording an EPS of -0.98 compared to the forecasted -0.71. Despite this miss, the ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Pfizer on Thursday made significant changes to its diversity, equity, and inclusion webpage, as companies across different industries seek to reposition their policies and messaging amid President ...

This page features the latest news about the Mineralys Therapeutics share. MLYS stock touches 52-week low at $8.57 amid market challenges Mineralys Therapeutics, Inc. (MLYS) stock has reached a ...

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a note issued to investors on Monday,Benzinga reports.

As Wall Street looks ahead to phase III data due soon with Mineralys Therapeutics Inc.’s lorundrostat for uncontrolled or resistant hypertension, analysts are also weighing the odds of the firm in ...

Results soon from Mineralys as others busy in aldosterone space Mineralys Therapeutics Inc. should have data shortly with lorundrostat for uncontrolled or resistant hypertension, a compound that may ...